Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GB:0MGB)
LSE:0MGB
Holding GB:0MGB?
Track your performance easily
0MGB Stock Chart & Stats
Day’s Rangekr0 - kr0
52-Week Rangekr1,432.00 - kr2,279.00
Previous Closekr1,458.71
Volume2.99K
Average Volume (3M)24.55K
Market Cap
kr95.26B
Enterprise Valuekr67.90B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)20.3
Beta0.59
Next Earnings
Feb 12, 2025EPS Estimate
kr24.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)71.88
Shares Outstanding65,691,573
10 Day Avg. Volume5,380
30 Day Avg. Volume24,551
Standard Deviation0.09
R-Squared0.18
Alpha0.00254
Financial Highlights & Ratios
Price to Book (P/B)34.65
Price to Sales (P/S)0.10
Price to Cash Flow (P/CF)0.90
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr2,508.17Price Target Upside71.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Genmab A/S News
Bulls Say, Bears Say
Bulls Say
Clinical DataPI/II data presented for Rina-S (FR α-targeted ADC) at ESMO in ovarian cancer was compelling with ORR of 50.0%, which is competitive on efficacy vs AbbVie’s Elahere.
Product LaunchEpkinly launch is progressing, with Genmab specifically highlighting strong Japan launch.
Revenue GrowthGenmab remains very comfortable in continued Darzalex revenue growth, with 1L penetration continuing to increase and share in 2L stable.
Bears Say
Earnings ForecastThere is significant downside to 2025 and 2026 EBIT forecasts, with increasing operating expenses not yet captured.
Earnings RiskNear-term risk exists that around Q3 results, the market increases focus on 2025/26 earnings power, prompting significant downgrades and potential share price downside.
Product Development UncertaintyUncertainty around JNJ’s opt-in decision on HexabodyCD38, given limited data and lengthy development timelines, could lead to a double-digit share-price move.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
15.11% Mutual Funds
<0.01% Other Institutional Investors
74.19% Public Companies and
Individual Investors
0MGB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest share price was kr1432.00 and its highest was kr2279.00 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 12, 2025 which is in 82 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 06, 2024. The company reported kr19.81 earnings per share for the quarter, missing the consensus estimate of kr20.99 by -kr1.18.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is kr24.4.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 66,176,834 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of kr19.81 in its last earnings report, missing expectations of kr20.99. Following the earnings report the stock price went up 2.202%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in GB:0MGB
---
Genmab A/S Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.62%
12-Months-Change
Fundamentals
Return on Equity
14.72%
Trailing 12-Months
Asset Growth
12.55%
Trailing 12-Months
Company Description
Genmab A/S
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
---
0MGB Stock 12 Month Forecast
Average Price Target
kr2,508.17
▲(71.94% Upside)
Technical Analysis
Best Analysts Covering 0MGB
1 Year
1 Year Success Rate
18/35 ratings generated profit
1 Year Average Return
+11.31%
assigned a buy rating yesterday
Copying Emily Field's trades and holding each position for 1 Year would result in 51.43% of your transactions generating a profit, with an average return of +11.31% per trade.
---